| Anurag Gupta, MD | |
|
106 La Casa Via Ste 140, Walnut Creek, CA 94598-3084 | |
| (925) 274-2860 | |
| (925) 932-4527 |
| Full Name | Anurag Gupta |
|---|---|
| Gender | Male |
| Speciality | Cardiac Electrophysiology |
| Experience | 22 Years |
| Location | 106 La Casa Via Ste 140, Walnut Creek, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255520623 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| John Muir Medical Center - Concord Campus | Concord, CA | Hospital |
| John Muir Medical Center - Walnut Creek Campus | Walnut creek, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| John Muir Physician Network | 6608789813 | 464 |
News Archive
Science is increasingly commuting the death sentence that is a diagnosis of multiple myeloma. A cancer of the plasma cells that primarily strikes the elderly, multiple myeloma has been deadly because patients have been unable to withstand the aggressive treatment necessary to combat it.
According to a new report from the Centre for Disease Prevention and Control (CDC) National Center for Health Statistics, only around 23 percent of the American adults meet the recommendations for aerobic and muscle-strengthening exercises.
Affymetrix, Inc. today announced that the U.S. Food and Drug Administration has cleared the addition of new gene expression reagents as accessories to its GeneChip Microarray Instrument System for in vitro diagnostic use, making Affymetrix the first in the industry to provide a comprehensive microarray-based clinical toolkit for diagnostic test development, signature discovery for companion diagnostics, and translational initiatives. Affymetrix Gene Profiling Reagents offer unparalleled convenience by simplifying assay workflow, decreasing hands-on time, and reducing quality control testing compared to research-use-only-produced products.
Two common operations for stress urinary incontinence help women achieve similar levels of dryness, according to a team of urologists and urogynecologists who compared the treatments in a large U.S. trial supported by the National Institutes of Health. The study is being released online May 17, 2010, by the New England Journal of Medicine to coincide with a presentation at the annual meeting of the American College of Obstetrics and Gynecology. Results will appear in the June 3 print edition.
GenVec, Inc. today reported financial results for the first quarter ended March 31, 2015. For the three months ended March 31, 2015, GenVec reported a net loss of $1.5 million, or $0.09 per share, on revenues of $0.4 million, compared with a net loss of $1.0 million, or $0.07 per share, on revenues of $2.1 million, for the same period in the prior year.
› Verified 9 days ago
| Entity Name | Stanford Health Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437292927 PECOS PAC ID: 6709797491 Enrollment ID: O20031124000348 |
News Archive
Science is increasingly commuting the death sentence that is a diagnosis of multiple myeloma. A cancer of the plasma cells that primarily strikes the elderly, multiple myeloma has been deadly because patients have been unable to withstand the aggressive treatment necessary to combat it.
According to a new report from the Centre for Disease Prevention and Control (CDC) National Center for Health Statistics, only around 23 percent of the American adults meet the recommendations for aerobic and muscle-strengthening exercises.
Affymetrix, Inc. today announced that the U.S. Food and Drug Administration has cleared the addition of new gene expression reagents as accessories to its GeneChip Microarray Instrument System for in vitro diagnostic use, making Affymetrix the first in the industry to provide a comprehensive microarray-based clinical toolkit for diagnostic test development, signature discovery for companion diagnostics, and translational initiatives. Affymetrix Gene Profiling Reagents offer unparalleled convenience by simplifying assay workflow, decreasing hands-on time, and reducing quality control testing compared to research-use-only-produced products.
Two common operations for stress urinary incontinence help women achieve similar levels of dryness, according to a team of urologists and urogynecologists who compared the treatments in a large U.S. trial supported by the National Institutes of Health. The study is being released online May 17, 2010, by the New England Journal of Medicine to coincide with a presentation at the annual meeting of the American College of Obstetrics and Gynecology. Results will appear in the June 3 print edition.
GenVec, Inc. today reported financial results for the first quarter ended March 31, 2015. For the three months ended March 31, 2015, GenVec reported a net loss of $1.5 million, or $0.09 per share, on revenues of $0.4 million, compared with a net loss of $1.0 million, or $0.07 per share, on revenues of $2.1 million, for the same period in the prior year.
› Verified 9 days ago
| Entity Name | John Muir Physician Network |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841407665 PECOS PAC ID: 6608789813 Enrollment ID: O20031226000143 |
News Archive
Science is increasingly commuting the death sentence that is a diagnosis of multiple myeloma. A cancer of the plasma cells that primarily strikes the elderly, multiple myeloma has been deadly because patients have been unable to withstand the aggressive treatment necessary to combat it.
According to a new report from the Centre for Disease Prevention and Control (CDC) National Center for Health Statistics, only around 23 percent of the American adults meet the recommendations for aerobic and muscle-strengthening exercises.
Affymetrix, Inc. today announced that the U.S. Food and Drug Administration has cleared the addition of new gene expression reagents as accessories to its GeneChip Microarray Instrument System for in vitro diagnostic use, making Affymetrix the first in the industry to provide a comprehensive microarray-based clinical toolkit for diagnostic test development, signature discovery for companion diagnostics, and translational initiatives. Affymetrix Gene Profiling Reagents offer unparalleled convenience by simplifying assay workflow, decreasing hands-on time, and reducing quality control testing compared to research-use-only-produced products.
Two common operations for stress urinary incontinence help women achieve similar levels of dryness, according to a team of urologists and urogynecologists who compared the treatments in a large U.S. trial supported by the National Institutes of Health. The study is being released online May 17, 2010, by the New England Journal of Medicine to coincide with a presentation at the annual meeting of the American College of Obstetrics and Gynecology. Results will appear in the June 3 print edition.
GenVec, Inc. today reported financial results for the first quarter ended March 31, 2015. For the three months ended March 31, 2015, GenVec reported a net loss of $1.5 million, or $0.09 per share, on revenues of $0.4 million, compared with a net loss of $1.0 million, or $0.07 per share, on revenues of $2.1 million, for the same period in the prior year.
› Verified 9 days ago
| Entity Name | University Healthcare Alliance |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760531198 PECOS PAC ID: 6305748799 Enrollment ID: O20040126000292 |
News Archive
Science is increasingly commuting the death sentence that is a diagnosis of multiple myeloma. A cancer of the plasma cells that primarily strikes the elderly, multiple myeloma has been deadly because patients have been unable to withstand the aggressive treatment necessary to combat it.
According to a new report from the Centre for Disease Prevention and Control (CDC) National Center for Health Statistics, only around 23 percent of the American adults meet the recommendations for aerobic and muscle-strengthening exercises.
Affymetrix, Inc. today announced that the U.S. Food and Drug Administration has cleared the addition of new gene expression reagents as accessories to its GeneChip Microarray Instrument System for in vitro diagnostic use, making Affymetrix the first in the industry to provide a comprehensive microarray-based clinical toolkit for diagnostic test development, signature discovery for companion diagnostics, and translational initiatives. Affymetrix Gene Profiling Reagents offer unparalleled convenience by simplifying assay workflow, decreasing hands-on time, and reducing quality control testing compared to research-use-only-produced products.
Two common operations for stress urinary incontinence help women achieve similar levels of dryness, according to a team of urologists and urogynecologists who compared the treatments in a large U.S. trial supported by the National Institutes of Health. The study is being released online May 17, 2010, by the New England Journal of Medicine to coincide with a presentation at the annual meeting of the American College of Obstetrics and Gynecology. Results will appear in the June 3 print edition.
GenVec, Inc. today reported financial results for the first quarter ended March 31, 2015. For the three months ended March 31, 2015, GenVec reported a net loss of $1.5 million, or $0.09 per share, on revenues of $0.4 million, compared with a net loss of $1.0 million, or $0.07 per share, on revenues of $2.1 million, for the same period in the prior year.
› Verified 9 days ago
| Entity Name | John Muir Trauma Physicians Billing Service |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093864837 PECOS PAC ID: 3476542515 Enrollment ID: O20050420001452 |
News Archive
Science is increasingly commuting the death sentence that is a diagnosis of multiple myeloma. A cancer of the plasma cells that primarily strikes the elderly, multiple myeloma has been deadly because patients have been unable to withstand the aggressive treatment necessary to combat it.
According to a new report from the Centre for Disease Prevention and Control (CDC) National Center for Health Statistics, only around 23 percent of the American adults meet the recommendations for aerobic and muscle-strengthening exercises.
Affymetrix, Inc. today announced that the U.S. Food and Drug Administration has cleared the addition of new gene expression reagents as accessories to its GeneChip Microarray Instrument System for in vitro diagnostic use, making Affymetrix the first in the industry to provide a comprehensive microarray-based clinical toolkit for diagnostic test development, signature discovery for companion diagnostics, and translational initiatives. Affymetrix Gene Profiling Reagents offer unparalleled convenience by simplifying assay workflow, decreasing hands-on time, and reducing quality control testing compared to research-use-only-produced products.
Two common operations for stress urinary incontinence help women achieve similar levels of dryness, according to a team of urologists and urogynecologists who compared the treatments in a large U.S. trial supported by the National Institutes of Health. The study is being released online May 17, 2010, by the New England Journal of Medicine to coincide with a presentation at the annual meeting of the American College of Obstetrics and Gynecology. Results will appear in the June 3 print edition.
GenVec, Inc. today reported financial results for the first quarter ended March 31, 2015. For the three months ended March 31, 2015, GenVec reported a net loss of $1.5 million, or $0.09 per share, on revenues of $0.4 million, compared with a net loss of $1.0 million, or $0.07 per share, on revenues of $2.1 million, for the same period in the prior year.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Anurag Gupta, MD 106 La Casa Via, #140, Walnut Creek, CA 94598 Ph: (925) 274-2860 | Anurag Gupta, MD 106 La Casa Via Ste 140, Walnut Creek, CA 94598-3084 Ph: (925) 274-2860 |
News Archive
Science is increasingly commuting the death sentence that is a diagnosis of multiple myeloma. A cancer of the plasma cells that primarily strikes the elderly, multiple myeloma has been deadly because patients have been unable to withstand the aggressive treatment necessary to combat it.
According to a new report from the Centre for Disease Prevention and Control (CDC) National Center for Health Statistics, only around 23 percent of the American adults meet the recommendations for aerobic and muscle-strengthening exercises.
Affymetrix, Inc. today announced that the U.S. Food and Drug Administration has cleared the addition of new gene expression reagents as accessories to its GeneChip Microarray Instrument System for in vitro diagnostic use, making Affymetrix the first in the industry to provide a comprehensive microarray-based clinical toolkit for diagnostic test development, signature discovery for companion diagnostics, and translational initiatives. Affymetrix Gene Profiling Reagents offer unparalleled convenience by simplifying assay workflow, decreasing hands-on time, and reducing quality control testing compared to research-use-only-produced products.
Two common operations for stress urinary incontinence help women achieve similar levels of dryness, according to a team of urologists and urogynecologists who compared the treatments in a large U.S. trial supported by the National Institutes of Health. The study is being released online May 17, 2010, by the New England Journal of Medicine to coincide with a presentation at the annual meeting of the American College of Obstetrics and Gynecology. Results will appear in the June 3 print edition.
GenVec, Inc. today reported financial results for the first quarter ended March 31, 2015. For the three months ended March 31, 2015, GenVec reported a net loss of $1.5 million, or $0.09 per share, on revenues of $0.4 million, compared with a net loss of $1.0 million, or $0.07 per share, on revenues of $2.1 million, for the same period in the prior year.
› Verified 9 days ago
Dr. Joseph Patrick Henry, M.D. Internal Medicine Medicare: May Accept Medicare Assignments Practice Location: 1220 Rossmoor Pkwy, Walnut Creek, CA 94595 Phone: 925-947-3393 Fax: 925-947-3396 | |
Mr. Ramin Khashayar, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1399 Ygnacio Valley Rd, Ste 14, Walnut Creek, CA 94598 Phone: 925-939-3050 Fax: 925-939-3057 | |
Dr. Hennessey Tseng, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1450 Treat Blvd, Suite 220b, Walnut Creek, CA 94597 Phone: 925-937-1770 Fax: 925-937-0630 | |
Dr. Ali-reza Barmaki, M.D. Internal Medicine Medicare: May Accept Medicare Assignments Practice Location: 1220 Rossmoor Pkwy, Walnut Creek, CA 94595 Phone: 925-947-3393 Fax: 925-947-3396 | |
Dr. Cynthia M. Mullen, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2637 Shadelands Dr, Walnut Creek, CA 94598 Phone: 925-322-2372 Fax: 925-322-6720 | |
Mr. David Nathanson, Internal Medicine Medicare: Medicare Enrolled Practice Location: 320 Lennon Ln, Walnut Creek, CA 94598 Phone: 925-906-2000 | |
Mark D Nathan, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 106 La Casa Via, #140, Walnut Creek, CA 94598 Phone: 925-274-2860 Fax: 925-932-4527 |